Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q6P9H5
UPID:
GIMA6_HUMAN
Alternative names:
Immunity-associated nucleotide 2 protein; Immunity-associated nucleotide 6 protein
Alternative UPACC:
Q6P9H5; C9J7B6; D3DWZ4; Q5ZPR6; Q9H612
Background:
The GTPase IMAP family member 6, known by its alternative names Immunity-associated nucleotide 2 protein and Immunity-associated nucleotide 6 protein, plays a crucial role in cellular processes. This protein, encoded by the gene with the UniProt accession number Q6P9H5, is involved in the regulation of intracellular signaling pathways that are essential for maintaining cellular homeostasis and responding to environmental stimuli.
Therapeutic significance:
Understanding the role of GTPase IMAP family member 6 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.